Advertisement
U.S. Markets close in 1 hr 32 mins

Roquefort Therapeutics plc (ROQ.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
4.5500-1.0500 (-18.75%)
At close: 04:29PM GMT

Roquefort Therapeutics plc

85 Great Portland Street
First Floor
London W1W 7LT
United Kingdom
44 20 3918 8633
https://www.roquefortplc.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 10

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen Paul West B.Com, CAExecutive Chairman152.9kN/A1972
Mr. Trevor Ajanthan ReginaldCEO & Executive Director305.8kN/A1972
Dr. Emma MorrisHead of Pre-Clinical ResearchN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.

Corporate Governance

Roquefort Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.